Skip to content

Studies

Benjamí Oller Salvia, PhD

Associate Professor - ERC Grantee

Department of Bioengineering



Training

EMBO Long-Term Fellow (MRC Laboratory of Molecular Biology, Cambridge, 2017-2019)MRC Postdoctoral Scientist (MRC Laboratory of Molecular Biology, Cambridge, 2016-2017)PhD in Organic Chemistry (University of Barcelona, 2015)MSc in Organic Chemistry (University of Barcelona, 2012)Degree in Chemistry (URL, 2010)


Experience

Associate Professor (IQS-URL, 2023-)
Assistant Professor (IQS-URL, 2019-present)


Research lines

  • Development of peptides for biomedical applications.
  • Generation of selectively modified therapeutic proteins by genetic code expansion and bioorthogonal chemistry.
  • Design of vectorised drug delivery systems, mainly targeting the brain.
  • Development of stimuli-responsive proteins and nanomaterials.

Programs

Research projects

OBGate (Creating an orthogonal gate to the brain)

Change of paradigm in the the field of brain delivery: opening a new Orthogonal Brain Gate where targeted drugs will be able to cross the blood brain barrier for the treatment of brain diseases
GEMAT – Materials Engineering

TargetGBM (nanomedicina contra tumores)

Generación de una nanopartícula polimérica estable, permeable al cerebro a traves de la barrera hematoencefálica  y dirigida para la administración sistémica de genes al glioblastoma
GEMAT – Materials Engineering

ACTIVATED (Anticuerpos activables en terapias dirigidas)

Desarrollo de un anticuerpo activable para dirigir un nanosistema de vectorización de terapias génicas a células madre de glioma
GEMAT – Materials Engineering

PRO-ANTIBODY (Activación selectiva de Anticuerpos contra el Glioblastoma)

Desarrollo de anticuerpos activables para la administración de terapias génicas en las células madre de glioma
GEMAT – Materials Engineering

APTIBody (Nanoterapias de Glioma)

Estrategia para generar anticuerpos activables y su aplicación para dirigir nanoterapias génicas a células madre de glioma
GEMAT – Materials Engineering

ADC2GBM (Development of brain-permeable masked nanobody-drug conjugates to eliminate glioma stem cells)

Innovative formulation to treat glioma using brain-permeable masked nanobody-drug conjugates.
GEMAT – Materials Engineering

Development of a chemogenetic strategy to generate conditionally-active antibodies targeting brain tumors

Activatable antibodies that target glioma stem cells in glioblastoma by activating only the tumour environment
GEMAT – Materials Engineering

BrainSAbs (Development of brain-shuttle smart antibody conjugates targeting brain tumors)

Developing an innovative technology in the field of brain delivery of biotherapies, specifically for brain metastatic breast cancer
GEMAT – Materials Engineering